Pregnant women with intrahepatic cholestasis of pregnancy (ICP) have an increased risk of other pregnancy-related problems, including gestational diabetes and preeclampsia, or sudden high…
News
CHOLANGITIS
NewsElafibranor, now Iqirvo, wins FDA accelerated approval for PBC
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Ipsen’s elafibranor as a second-line treatment for primary biliary cholangitis (PBC).
FATTY LIVER DISEASE
NewsIn NASH, VK2809 treatment reduces liver fat, fibrosis: Phase 2b trial
One year of treatment with Viking Therapeutics’ candidate VK2809 safely and effectively reduces liver fat content, damage, and scarring in adults with nonalcoholic steatohepatitis…
BILIARY ATRESIA
NewsHolomedicine aids liver transplant for girl with biliary atresia
An imaging technique called holomedicine helped surgeons in Singapore make sure they removed a part of a liver from a living adult donor that was…
Vir Biotechnology’s investigational therapy tobevibart, used alone or in combination with another company candidate called elebsiran, can reduce hepatitis D virus (HDV) levels and…
CHOLANGITIS
News1st patient enrolled in WIND-PSC natural history study
The first patient has been enrolled in WIND-PSC, a global study to track the natural course of primary sclerosing cholangitis (PSC) and generate real-world…
CHOLESTASIS
NewsEMA committee favors approval of Livmarli for PFIC in EU
Note: This story was updated July 9, 2024, to clarify Livmarli is approved in the U.S. for all PFIC forms, but not recommended for a…
FATTY LIVER DISEASE
NewsHealthWell Foundation opens fund for MASH patients in US
The HealthWell Foundation, a charity that helps people who can’t afford to pay their medical bills, has started a new fund to support those…
FATTY LIVER DISEASE
NewsUS doctors prescribe Rezdiffra, note concern about patient costs
Physicians from the GI Alliance, the largest physician-led network of gastroenterologists in the U.S., are now actively prescribing Rezdiffra (resmetirom) to eligible people…
ALAGILLE SYNDROME
NewsLivmarli helps Alagille patients stop other anti-itch meds in real world
About one year of treatment with Livmarli (maralixibat) allows about a third of patients with Alagille syndrome to stop at least one other…
Recent Posts
- Clinical trial results support bepirovirsen for hepatitis B
- Vitamin D may help protect against liver damage in those with PBC: Study
- Think smoking only affects your lungs? Your liver would like a word.
- Low vitamin D in early pregnancy tied to ICP risk, if fetus is a girl
- This year, my son with Alagille will hit 2 major childhood milestones